Diclofenac potassium
Modify Date: 2025-08-21 09:04:12
Diclofenac potassium structure
|
Common Name | Diclofenac potassium | ||
|---|---|---|---|---|
| CAS Number | 15307-81-0 | Molecular Weight | 334.239 | |
| Density | N/A | Boiling Point | 412ºC at 760 mmHg | |
| Molecular Formula | C14H10Cl2KNO2 | Melting Point | 156-158ºC | |
| MSDS | Chinese USA | Flash Point | 203ºC | |
| Symbol |
GHS07, GHS09 |
Signal Word | Warning | |
Use of Diclofenac potassiumDiclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3]. |
| Name | diclofenac potassium |
|---|---|
| Synonym | More Synonyms |
| Description | Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3]. |
|---|---|
| Related Catalog | |
| Target |
Human COX-2:1.3 nM (IC50, in CHO cells) Human COX-1:4 nM (IC50, in CHO cells) Ovine COX-2:0.84 nM (IC50) Ovine COX-1:5.1 nM (IC50) |
| In Vitro | Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an IC50 of 7±3 nM[1]. Diclofenac (1-60 μM; 1 day) induces neural stem cells (NSCs)death in a concentration-dependent manner[3]. Diclofenac (10-60 μM; 6 hours) increases the expression of cleaved (activated) caspase-3[3]. Cell Viability Assay[3] Cell Line: Neural stem cells (NSCs) Concentration: 1, 3, 10, 30, 60 μM Incubation Time: 1 day Result: Induction of cell death was concentration-dependent and the effect was not saturated at a concentration of up to 60 μM. Western Blot Analysis[3] Cell Line: Neural stem cells (NSCs) Concentration: 10, 30 or 60 μM Incubation Time: 6 hours Result: The activation of caspase-3 was increased in a concentration-dependent manner. |
| In Vivo | Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal 51Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days[1]. Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats[1]. Animal Model: Male Sprague-Dawley rats (150±200 g)[1] Dosage: 3 mg/kg Administration: Oral administration, b.i.d., for 5 days Result: Resulted in a significant increase in faecal 51Cr excretion. Animal Model: Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model[2] Dosage: 10 mg/kg Administration: Administered via oral route just prior to induction of inflammation Result: Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h). |
| References |
| Boiling Point | 412ºC at 760 mmHg |
|---|---|
| Melting Point | 156-158ºC |
| Molecular Formula | C14H10Cl2KNO2 |
| Molecular Weight | 334.239 |
| Flash Point | 203ºC |
| Exact Mass | 332.972565 |
| PSA | 52.16000 |
| LogP | 3.10240 |
| Vapour Pressure | 1.59E-07mmHg at 25°C |
| Symbol |
GHS07, GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H411 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Codes | T: Toxic; |
| Risk Phrases | 22-51/53 |
| Safety Phrases | 61 |
| RIDADR | 2811.0 |
| HS Code | 2922499990 |
| HS Code | 2922499990 |
|---|---|
| Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |
|
The advantages and limitations of the analgesics available for control of postoperative pain after a dental procedure.
SAAD Dig. 29 , 70-81, (2013)
|
|
|
Chitosan/glucose 1-phosphate as new stable in situ forming depot system for controlled drug delivery.
Eur. J. Pharm. Biopharm. 88(2) , 361-73, (2014) Chitosan (CS)-based thermosensitive solutions that turn into semi-solid hydrogels upon injection at body temperature have increasingly drawn attention over the last decades as an attractive new type o... |
|
|
Cystoid macular edema from cancer-associated retinopathy.
Optom. Vis. Sci. 91(4 Suppl 1) , S66-70, (2014) This article reviews the diagnosis and management of a patient with cancer-associated retinopathy (CAR) secondary to small cell lung cancer who developed a rare presentation of CAR, cystoid macular ed... |
| Diclofenic potassium |
| Potassium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, potassium salt (1:1) |
| potassium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate |
| 2-((2,6-Dichlorophenyl)amino)benzeneacetic Acid Monopotassium Salt |
| Diclofenac potassium |
| 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid, potassium salt |
| Potassium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate |
| UNII-L4D5UA6CB4 |
| MFCD00082254 |
| Cataflam |
| CGP 45840B |
| CGP-45840B |
| 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid potassium salt, Diclofenac potassium salt |